Tuberculosis (TB) Toolbox

Under the coordination of the Nunavik Public Health Department, this TB toolbox brings together all the tuberculosis assessment and follow-up protocols and documents used at regional level in Nunavik's two health centers.

Its objectives are to :

  • standardize tuberculosis clinical and public health practice guidelines at regional level;
  • support and guide the interventions of the various professionals involved in tuberculosis control.

It is the fruit of consultation and consensus-building between all institutional and professional partners involved in the regional fight against tuberculosis.

This TB toolbox is regularly updated and improved with the gradual addition of new tools.

Definition of a priority village :

Village with the highest risk of recent TB transmission, based on epidemiological indicators such as the number of recent smear-positive TB cases in the community, the number of recent infections that have been identified, and the historical burden of TB and LTBI. Each village is assigned a score based on these indicators and adjusted according to its population size; on this basis, a village can then be classified as a "priority village" for tuberculosis.

List of priority villages drawn up by the Public Health Department:

  • Puvirnituq
  • Akulivik
  • Salluit
  • Kangiqsualujjuaq
  • Kangiqsujuaq
  • Inukjuak
  • Ivujivik
1ère diffusionMise à jour
Roles and responsibilities of TB interveners in Nunavik2023-10-022023-10-01
Guide to use of TB tools: Dashboard2023-10-022023-10-01
Prescription of LTBI medication1èrediffusionMise à jour
Prescription of LTBI medication – 3HP2024-04-172024-04-16
Prescription of LTBI medication - RIF2023-10-022024-03-14
Prescription of LTBI medication – INH DOT2023-10-022024-03-14
Prescription of LTBI medication – INH daily2023-10-022024-03-14
Prescription of LTBI medication – 3HP window-period2024-04-172024-04-16
Prescription of LTBI medication - RIF window-period2023-10-022024-03-14

LTBI follow-up protocols		  
Follow-up protocol – 3HP2024-04-172024-09-03
Follow-up protocol - RIF2023-10-022024-09-03
Follow-up protocol – INH Daily and DOT2023-10-022024-09-03
Follow-up protocol – 3HP window-period2024-04-172024-04-16
Follow-up protocol – RIF window-period2023-10-022023-10-01

Registration of the LTBI medication		  
Registration of the medication – 3HP2024-04-172024-09-10
Registration of the medication - RIF2023-10-022023-10-01
Registration of the medication – INH DOT2023-10-022023-10-01
Registration of the medication – INH daily2023-10-022023-10-01

Compliance curve		  
Compliance curve – RIF2023-10-022024-05-17
Compliance curve – INH daily2023-10-022024-05-17

Clinical assessment		  
Adverse reactions of the main TB treatments2023-10-022023-10-01
Weekly clinical assessment – 3HP2024-04-172024-04-16
Monthly clinical assessment – RIF / INH DIE / INH TOD2020-03-252023-10-02

Clinical and radiological follow-up		  
Clinical and radiological follow-up guide2023-10-022024-08-27
STANDARD clinical and radiological follow-up - Clinical evaluation and medical action2023-10-022023-10-01
ADDITIONAL clinical and radiological follow-up - Clinical evaluation and medical action2023-10-022023-10-01
Déclaration MADO1èrediffusionMise à jour
Reportable diseases form (available in French only)2023-10-022023-10-01
Reportable diseases form – dynamic version (available in French only)2023-10-022023-10-01

Appendix 4		  
Appendix 42023-10-022023-10-01

Identification of contacts of an active TB case		  
Procedure for identification of contacts of an active TB case2023-10-0252023-10-01
Identification of contacts of an active TB case2023-10-022024-01-18

Commitment contract 		  
Procedure for commitment contract relative to mandatory treatment2023-10-022023-10-01
Commitment contract relative to mandatory treatment 2023-10-022023-10-01

Home isolation		  
Procedure for home isolation2020-03-252023-10-01
Home isolation – Instructions to follow - Inuktitut2023-10-022023-10-01
Home isolation – Instructions to follow - English2023-10-022023-10-01
Home isolation – Instructions to follow - French2023-10-022023-10-01

Prescription of active TB medication		  
--Adult--  
Prescription of active TB medication – Phase 1 - Adult2023-10-022024-03-14
Prescription of active TB medication – Phase 2 - Adult2023-10-022024-03-14
--Child--  
Prescription of active TB medication – Phase 1 - Child2023-10-022024-05-14
Prescription of active TB medication – Phase 2 - Child2023-10-022024-03-14

Active TB follow-up protocol		  
Active TB follow-up protocol2023-10-022024-09-03

Registration of the active TB medication		  
Procedure - Registration of the active TB medication2023-10-012023-04-04
Registration of the active TB medication – Phase 12023-10-022023-10-01
Registration of the active TB medication – Phase 22023-10-022023-10-01

Monthly clinical assessment		  
Adverse reactions of the main TB treatments2023-10-022023-10-01
Monthly clinical assessment2023-10-022023-10-01

Treatment outcome		  
Treatment outcome2023-10-022023-10-01

Clinical and radiological follow-up		  
Clinical and radiological follow-up guide2023-10-022024-08-27
STANDARD clinical and radiological follow-up - Clinical evaluation and medical action2023-10-022023-10-01
ADDITIONAL clinical and radiological follow-up - Clinical evaluation and medical action2023-10-022023-10-01
1ère diffusionMise à jour
Patient education
Talking tuberculosis – An educational resource – By Health Canada 2022-06-082015-04
Information for workers
Tuberculosis screening of certain workers in Nunavik 2024-06-132023-09-21

The tools contained in this section are reserved for use in a mass screening context only, according to the communities targeted below.

Mass (or population) screening applies to an entire population or a large group of them, is characterized by the absence of individual selection criteria, and is organized as part of a public health campaign.

It thus differs from individual screening, which is indicated by criteria specific to the individual, such as exposure to a person with active TB or the presence of TB symptoms.

Target audience: All interveners assigned to TB-related tasks (Public Health nurses, TB nurses, physicians tasked with TB monitoring) and any other interested interveners

Reminder:

  • The capsule “Immunisation - Registre de vaccination du Québec - SI-PMI” is accredited.
  • The other capsules are not accredited.
  • For employees of the IHC and the UTHC, time spent on training is paid upon authorization by the employer.

Access procedures: To receive the links to access the various training capsules, fill out the form.

1stdiffusionUpdated
Issues in Indigenous health

Presentation PDF
Duration: 1 h 15 m
Content:

  • History of the Inuit
  • Intergenerational trauma
  • Inuit model for health
  • Cultural safety of health care
2023-042023-04
PHO program

Presentation PDF
Duration: 15 m
Content:

  • Who are the PHOs? What do they do?
  • Pilot project
  • Training program
  • McGill research project
2023-042023-04
TB 101

Presentation PDF
Duration: 2 h
Content:

  • Natural history of tuberculosis: transmission
  • Clinical signs of latent tuberculosis infection (LTBI)
  • Clinical signs of active tuberculosis (TB)
  • Diagnostic procedures for TB:
    • Clinical assessment
    • Tuberculin skin test (TST)
    • Pulmonary radiography
    • Taking respiratory specimens
2020-042022-08
TB 201

 

Presentation PDF
Duration: 1 h 30 m
Content:

  • Vaccination against tuberculosis
  • Treatment of LTBI
  • Treatment of active TB
  • Window-period prophylaxis
2020-042022-08
TB 301

 

Presentation PDF
Duration: 3 h
Content:

  • Tools for diagnostic investigations
  • Tools for monitoring an LTBI patient
  • Tools for monitoring a patient with active TB
2022-082022-08
TB 401

PDF de présentation
Durée : 1h
Contenu :

  • Présentation du traitement ITL avec le 3HP
2024-062024-06
Cardex TB (for IHC interveners only)

Presentation PDF
Duration: 45 m
Content:

  • General presentation of the Cardex TB tool
  • Objectives of Cardex TB
  • Who fills out Cardex TB?
  • Where is Cardex TB found?
  • Detailed presentation on Cardex TB
  • Presentation of a series of tasks
  • Useful tips
  • Points to keep in mind
2023-042023-04
TST technique

Duration: 7 m
Content:

  • Before, during and after a TST
N/AN/A
Immunization – Québec immunization register - SI-PMI

Duration:1 h
Content:

  • Use of various functions available in the Quebec immunization register SI-PMI
N/AN/A
Capturing the TST in the SI-PMI

Presentation PDF
Duration: 20 m
Content:

  • Particularities for registering TSTs in the SI-PMI
2023-042024-02-27

To receive an alert when a tool is updated or when a new tool is added, register on our mailing list by sending an e-mail to: aurelie.heurtebize@ssss.gouv.qc.ca